Major histocompatibility complex associations with systemic lupus erythematosus.
This study focused on clinical subsets within systemic lupus erythematosus (SLE) in order to identify more homogeneous patient groups in which to define disease susceptibility gene(s). Analysis of the major histocompatibility complex gene products and genes with major histocompatibility complex class II and class III locus-specific probes and oligonucleotide probes for selected human leukocyte antigen DQ-beta alleles showed significant increases of human leukocyte antigen DR2 and the rare DQ-beta allele DR2-DQw1.AZH in the lupus nephritis patients compared with lupus patients without renal disease (relative risk = 8.3). C4A null was detected in one third of all of the SLE patients. In two thirds of the C4A null patients this was due to a DR3-associated C4A gene deletion. The remaining third may have a regulatory defect and this was DR2-associated. DR4 was significantly decreased in the nephritis patients in comparison with the non-renal SLE patients (relative risk = 0.3). A novel DQ-beta gene has been sequenced from two SLE patients that has not been observed in the normal population. Potential implications of these findings are discussed.
Fronek
Z
Z
Department of Microbiology and Immunology, Stanford University Medical Center, California.
Timmerman
L A
LA
Alper
C A
CA
Hahn
B H
BH
Kalunian
K
K
Peterlin
B M
BM
McDevitt
H O
HO
D003175:Complement C2 / Q000235:genetics; D003181:Complement C4 / Q000235:genetics; D006681:HLA-D Antigens / Q000235:genetics; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000208:ethnology / Q000235:genetics*; D008181:Lupus Nephritis / Q000235:genetics; D008285:Major Histocompatibility Complex; D008297:Male; D012150:Polymorphism, Restriction Fragment Length
D003175:Complement C2; D003181:Complement C4; D006681:HLA-D Antigens